오믹스 기반 임상시험 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 단계별, 연구 디자인별, 적응증별, 지역별 부문, 경쟁(2020-2030년)
Omics-Based Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase, By Study Design, By Indication, By Region & Competition, 2020-2030F
상품코드:1691774
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
오믹스 기반 임상시험 세계 시장 규모는 2024년 266억 7,000만 달러로 평가되었고, 예측 기간 동안 큰 폭으로 성장할 것으로 예상되며, 2030년까지 연평균 성장률(CAGR)은 7.25%를 나타낼 것으로 예상됩니다.
오믹스 기반 임상시험임상 연구에 참여하는 환자로부터 상세한 분자 데이터를 수집하기 위해 첨단 오믹스 기술을 통합합니다. 오믹스에는 생물학 및 의학에서 생체 분자를 분자 수준에서 분석하는 데 사용되는 다양한 고처리량 기술이 포함됩니다. 이러한 기술에는 유전체학(유전자와 DNA 연구), 단백질체학(단백질 연구), 대사체학(저분자 및 대사체 연구), 전사체학(RNA 및 유전자 발현 연구) 등이 포함됩니다. 오믹스 기반 임상시험의 주요 목적은 분자 프로파일을 기반으로 환자를 하위 그룹으로 세분화하여 보다 타겟팅된 맞춤형 의료 개입을 가능하게 하는 것입니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
266억 7,000만 달러
시장 규모 : 2030년
402억 6,000만 달러
CAGR : 2025-2030년
7.25%
급성장 부문
중재 연구
최대 시장
북미
그러나 오믹스 기반 임상시험은 데이터 표준화, 재현성 문제, 고도의 바이오인포매틱스 기능의 필요성 등의 과제에 직면해 있습니다. 성공적인 임상시험을 위해서는 오믹스 데이터의 정확성과 신뢰성이 매우 중요합니다. 예를 들어, 2024년 4월에 발표된 논문에서는 대사기능장애에 따른 지방간질환(MASLD) 관리에 있어 오믹스 기반 바이오마커의 중요성이 증가하고 있음을 강조하고 있습니다. 오믹스 기반 임상시험의 채택이 증가함에 따라 시장 성장이 더욱 촉진될 것으로 예상됩니다.
The global Omics-Based Clinical Trials Market was valued at USD 26.67 billion in 2024 and is projected to experience substantial growth during the forecast period, with a compound annual growth rate (CAGR) of 7.25% through 2030. Omics-based clinical trials integrate advanced omics technologies to collect detailed molecular data from patients participating in clinical studies. Omics encompasses a range of high-throughput techniques used in biology and medicine to analyze biological molecules at the molecular level. These techniques include genomics (the study of genes and DNA), proteomics (the study of proteins), metabolomics (the study of small molecules and metabolites), transcriptomics (the study of RNA and gene expression), and more. A key objective of omics-based clinical trials is to stratify patients into subgroups based on their molecular profiles, enabling more targeted and personalized healthcare interventions.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 26.67 Billion
Market Size 2030
USD 40.26 Billion
CAGR 2025-2030
7.25%
Fastest Growing Segment
Interventional Studies
Largest Market
North America
However, omics-based clinical trials face challenges such as data standardization, reproducibility issues, and the need for advanced bioinformatics capabilities. The accuracy and reliability of omics data are crucial for successful trials. For example, an article published in April 2024 highlights the growing significance of omics-based biomarkers in managing metabolic dysfunction-associated steatotic liver disease (MASLD), where these biomarkers aid in risk stratification and identifying patients with advanced fibrosis who are at higher risk of adverse outcomes. The increasing adoption of omics-based clinical trials is expected to further propel market growth.
Key Market Drivers:
Advancements in Omics Technologies
Recent developments in high-throughput sequencing have made these techniques faster, more precise, and cost-effective. Technologies like single-cell sequencing enable the examination of genetic material at an individual cell level, revealing cellular heterogeneity. Mass spectrometry tools have become more sensitive and precise, allowing the identification and quantification of proteins and metabolites in complex biological samples. Additionally, advancements in mass spectrometry imaging (MSI) enable the spatial mapping of molecules within tissues. Cryo-electron microscopy (cryo-EM) has revolutionized the structural analysis of proteins, achieving near-atomic resolution. X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy continue to enhance molecular structure resolution. Technologies such as stable isotope labeling and flux analysis offer insights into metabolic pathways, while quantitative proteomics methods, including isobaric labeling and label-free approaches, allow precise protein quantification.
A report from the Mayo Clinic in February 2023 highlights a new approach in genomics research, shifting some omics studies from traditional settings like hospitals to individuals' homes, particularly in rural and underserved areas. This change is expected to improve access to clinical trials, expanding participant pools and enabling more diverse data collection.
Key Market Challenges:
Sample Size and Diversity
One of the challenges of omics-based clinical trials is obtaining an adequate number of patient samples, particularly for rare diseases or genetically specific subpopulations. The availability of diverse patient samples is crucial, as these trials often require large and varied cohorts to generate reliable results. Biological variability among patients within the same disease category can be substantial, making it necessary to include larger sample sizes for statistical validity. Furthermore, ensuring genetic and ethnic diversity in clinical trial populations is essential for the broader applicability of findings. Omics-based trials often involve subgroup analysis based on genetic or molecular characteristics, and recruiting patients that meet these specific criteria can be time-consuming and resource-intensive. Delays in recruitment and data collection can hinder the trial process. Additionally, obtaining informed consent for genetic and molecular profiling, as well as addressing privacy concerns, can also present challenges.
The integration and interpretation of large, complex omics data sets also require advanced bioinformatics tools, which can further complicate the analysis, especially when dealing with large and diverse sample sizes.
Key Market Trends:
Integration of Multi-Omics Data
Different omics technologies provide unique perspectives on the molecular mechanisms underlying diseases. Integrating data from multiple omics disciplines offers a more comprehensive view of disease processes by examining the interplay of genes, proteins, metabolites, and other factors. This integration enhances the identification and validation of biomarkers for disease diagnosis, prognosis, and treatment response. Combining genetic, proteomic, and metabolic profiles leads to more accurate and robust biomarker discovery.
The integration of multi-omics data is pivotal for patient stratification, allowing researchers to classify patients based on molecular profiles and design more targeted clinical trials. This approach also facilitates the development of personalized therapies tailored to individual genetic, proteomic, and metabolic characteristics, leading to more effective treatments. In drug development, multi-omics integration helps to understand how drugs interact with various molecular components, providing insights into potential adverse effects and guiding drug design. For complex diseases like cancer, multi-omics data integration aids in understanding intricate molecular interactions, facilitating the identification of novel therapeutic targets and strategies. This integration aligns with a systems biology approach, offering a holistic understanding of biological systems as interconnected networks of genes, proteins, and metabolites.
Key Market Players:
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer Inc.
Covance Inc.
Novo Nordisk
Rebus Bio
Report Scope:
This report segments the global omics-based clinical trials market into various categories and provides a comprehensive analysis of market trends:
By Phase:
Phase I
Phase II
Phase III
Phase IV
By Study Design:
Expanded Access Studies
Interventional Studies
Observational Studies
By Indication:
Cardiology
CNS Diseases
Genetic Diseases
Immunology
Oncology
Respiratory Diseases
Skin Diseases
By Region:
North America: United States, Canada, Mexico
Asia-Pacific: China, India, South Korea, Australia, Japan
Europe: Germany, France, United Kingdom, Spain, Italy
South America: Brazil, Argentina, Colombia
Middle East & Africa: South Africa, Saudi Arabia, UAE
Competitive Landscape:
This section provides detailed analysis and profiles of the major players in the global omics-based clinical trials market.
Available Customizations:
TechSci Research offers tailored customization options for this market report. These include a detailed analysis of additional market players (up to five) as per specific company needs.
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Omics-Based Clinical Trials Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV.)
5.2.2. By Study Design (Expanded Access Studies, Interventional Studies, and Observational Studies)
5.2.3. By Indication (Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. Asia Pacific Omics-Based Clinical Trials Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Phase
6.2.2. By Study Design
6.2.3. By Indication
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Omics-Based Clinical Trials Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Phase
6.3.1.2.2. By Study Design
6.3.1.2.3. By Indication
6.3.2. India Omics-Based Clinical Trials Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Phase
6.3.2.2.2. By Study Design
6.3.2.2.3. By Indication
6.3.3. Australia Omics-Based Clinical Trials Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Phase
6.3.3.2.2. By Study Design
6.3.3.2.3. By Indication
6.3.4. Japan Omics-Based Clinical Trials Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Phase
6.3.4.2.2. By Study Design
6.3.4.2.3. By Indication
6.3.5. South Korea Omics-Based Clinical Trials Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Phase
6.3.5.2.2. By Study Design
6.3.5.2.3. By Indication
7. Europe Omics-Based Clinical Trials Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Phase
7.2.2. By Study Design
7.2.3. By Indication
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Omics-Based Clinical Trials Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Phase
7.3.1.2.2. By Study Design
7.3.1.2.3. By Indication
7.3.2. Germany Omics-Based Clinical Trials Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Phase
7.3.2.2.2. By Study Design
7.3.2.2.3. By Indication
7.3.3. Spain Omics-Based Clinical Trials Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Phase
7.3.3.2.2. By Study Design
7.3.3.2.3. By Indication
7.3.4. Italy Omics-Based Clinical Trials Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Phase
7.3.4.2.2. By Study Design
7.3.4.2.3. By Indication
7.3.5. United Kingdom Omics-Based Clinical Trials Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Phase
7.3.5.2.2. By Study Design
7.3.5.2.3. By Indication
8. North America Omics-Based Clinical Trials Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Phase
8.2.2. By Study Design
8.2.3. By Indication
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Omics-Based Clinical Trials Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Phase
8.3.1.2.2. By Study Design
8.3.1.2.3. By Indication
8.3.2. Mexico Omics-Based Clinical Trials Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Phase
8.3.2.2.2. By Study Design
8.3.2.2.3. By Indication
8.3.3. Canada Omics-Based Clinical Trials Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Phase
8.3.3.2.2. By Study Design
8.3.3.2.3. By Indication
9. South America Omics-Based Clinical Trials Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Phase
9.2.2. By Study Design
9.2.3. By Indication
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Omics-Based Clinical Trials Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Phase
9.3.1.2.2. By Study Design
9.3.1.2.3. By Indication
9.3.2. Argentina Omics-Based Clinical Trials Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Phase
9.3.2.2.2. By Study Design
9.3.2.2.3. By Indication
9.3.3. Colombia Omics-Based Clinical Trials Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Phase
9.3.3.2.2. By Study Design
9.3.3.2.3. By Indication
10. Middle East and Africa Omics-Based Clinical Trials Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Phase
10.2.2. By Study Design
10.2.3. By Indication
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Omics-Based Clinical Trials Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Phase
10.3.1.2.2. By Study Design
10.3.1.2.3. By Indication
10.3.2. Saudi Arabia Omics-Based Clinical Trials Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Phase
10.3.2.2.2. By Study Design
10.3.2.2.3. By Indication
10.3.3. UAE Omics-Based Clinical Trials Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Phase
10.3.3.2.2. By Study Design
10.3.3.2.3. By Indication
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Omics-Based Clinical Trials Market: SWOT Analysis
